AtCor Medical - News 2007

1. The major increase in both contracted and recognised revenue.
2. The healthy geographic spread of this revenue with all regions of the world performing well.
3. The emergence of the significant opportunity that the pharma sector presents.
4. The continued endorsement of our technology through, for example:
a. the guidelines issued jointly by the European Society of Hypertension and the European Society of Cardiology which state that important drug effects can only be seen with central pressure measurement and not using traditional brachial (cuff) blood pressure monitoring; and,
b. the US National Institute of Health (NIH) funded Strong Heart study that found that central pulse pressure was a superior predictor of all cardiovascular events than brachial pulse pressure.
5. The award of a $2.0 million commercial ready grant by AusIndustry to fund our next generation technology.

Please click here to view the ASX/media release

AtCor Medical announces FY2007 contracted revenue increases 86% to $6.3 m

26 July 2007

AtCor Medical today announced record sales for FY2007. New business closed in FY2007 of $6.3 million is an 86 per cent increase over FY2006 ($3.4 million) and comprises $4.8 million (unaudited) in recognised revenue for FY2007 and a further $1.5 million which will be recognised in future periods.

Please click here to view the ASX/media release

AtCor Medical announces fourth quarter report - Appendix 4C

26 July 2007

AtCor Medical today released its quarterly cash flow report for the period ending 30 June 2007. The company has $6,999,000 in cash and equivalents.

Please click here to view the ASX/media release

AtCor announces pharmaceutical trial contract with new US client

18 July 2007

AtCor Medical today announced that it has signed a contract to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company, headquartered in the United States.

Please click here to view the ASX/media release

AtCor Signs US$1.3 Million New Pharmaceutical Contracts

3 July 2007

AtCor Medical has signed agreements with two leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States. The total value of the contracts is approximately US $1.3 million.

Please click here to view the ASX/media release

AtCor Appoints Distributors for China and India

7 June 2007

AtCor Medical has strengthened its Asian sales network with the appointment of distributors in the People's Republic of China and India. The company has also re-signed distributors in Malaysia and Singapore.

Please click here to view the ASX/media release

US National Institute of Health funded trial concludes: Central pulse pressures a better predictor of cardiovascular risk and disease

29 May 2007

AtCor Medical today announced that the results from the US National Institute of Health’s funded Strong Heart Study have concluded central blood pressures are a better predictor of future cardiovascular outcomes than traditional brachial (cuff) blood pressure.

Please click here to view the ASX/media release

AtCor Awarded $2 Million Commercial Ready Grant

23 May 2007

AtCor Medical today announced that it has been awarded a grant of approximately $2 million through the Australian Government's AusIndustry Commercial Ready program.

Please click here to view the ASX/media release

AtCor Extends Distribution to Eastern Europe

30 April 2007

AtCor Medical has expanded its European distribution network to sixteen countries with the appointment of distributors in Eastern Europe.

Please click here to view the ASX/media release

AtCor Medical and Encorium Group, Inc. Announce Alliance for Clinical Research Trials

21 March 2007

AtCor Medical and Encorium Group Inc., an international, full service contract research organization (CRO) that provides comprehensive clinical solutions for pharmaceutical, biotechnology and medical device companies, today announced a joint marketing agreement for products and services that is anticipated to strengthen the fundamental value offerings of both companies.

Please click here to view the ASX/media release

Investor Update March 2007

16 March 2007

AtCor Medical today released their Investor Presentation for March 2007.

Please click here to view the ASX/media release

US gridiron players' central blood pressures tested during Super Bowl Week

13 February 2007

AtCor Medical advises that the SphygmoCor system was used to assess retired NFL players' cardiovascular risk during Super Bowl Week in the United States. These monitoring sessions, which generated print, broadcast and internet media coverage, helped to raise awareness of the importance of measuring central blood pressure using SphygmoCor.

An interview with Dr Roberts, founder and head of The Living Heart Foundation which sponsored the testing at Miami, can be seen via the link below. Dr Roberts is a retired cardiac surgeon and former quarterback for the Cleveland Browns and Miami Dolphins.

Please click here to view the interview

Please click here to view the ASX/media release

52% increase in first half sales

24 January 2007

AtCor Medical announces a 52 per cent increase in unaudited H1 FY2007 sales over H1 FY2006. Sales revenue for the six months ended 31 December 2006 was $2.6 million, compared to $1.7 million for the previous corresponding period.

In the United States, sales increased by 90 per cent in H1 FY2007 compared to H1 FY2006, and sales opportunities also increased significantly. In Europe, new distribution agreements and expanded contracts with existing distributors helped sales grow by 67 per cent.

Please click here to view the ASX/media release